# ViferaXS funding rounds and investors

As of 8 Nov 2026, ViferaXS has 1 verified round on record, none with a disclosed amount; latest: up to €12M incl. grants Series A led by Huma and SPRIND, announced 23 Sep 2026.

A clinical-stage biotechnology company developing peptide-based cancer immunotherapy for hematologic malignancies and solid tumors

Website: https://viferaxs.com  
Headquarters: Tübingen, Germany  
Page: https://fireround.dev/companies/viferaxs

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2026-09-23 | Series A | undisclosed | Huma, SPRIND | none named | [prnewswire.com](https://www.prnewswire.com/de/pressemitteilungen/viferaxs-raises-12-million-to-advance-phase-ii-trial-in-chronic-lymphocytic-leukemia-and-expand-its-oncology-pipeline-302886535.html), [prnewswire.com](https://www.prnewswire.com/news-releases/viferaxs-raises-12-million-to-advance-phase-ii-trial-in-chronic-lymphocytic-leukemia-and-expand-its-oncology-pipeline-302886700.html), [biospace.com](https://www.biospace.com/press-releases/viferaxs-raises-12-million-to-advance-phase-ii-trial-in-chronic-lymphocytic-leukemia-and-expand-its-oncology-pipeline) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.